Filtered By:
Condition: Renal Failure
Drug: Methylprednisolone
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 176 results found since Jan 2013.
Rationale and design of the Steroids in Cardiac Surgery trial
Conclusions: SIRS will lead to a better understanding of the safety and efficacy of prophylactic steroids for cardiac surgery requiring CBP.
Source: American Heart Journal - March 3, 2014 Category: Cardiology Authors: Richard Whitlock, Kevin Teoh, Jessica Vincent, P.J. Devereaux, Andre Lamy, Domenico Paparella, Yunxia Zuo, Daniel I. Sessler, Pallav Shah, Juan-Carlos Villar, Ganesan Karthikeyan, Gerard Urrútia, Alvaro Alvezum, Xiaohe Zhang, Seyed Hesameddin Abbasi, Hon Tags: Trial Design Source Type: research
Digital Subtraction Angiography (DSA) Arch Run in Place of CT Vessel and Perfusion Imaging: Proof of Concept (P1.014)
CONCLUSIONS: In both cases, DSA arch runs generated adequate, rapid vessel imaging including demonstration of collaterals in place of CTA/CTP. This minimized delays in treatment, provided information key to predicting benefit and facilitated a shorter time to reperfusion. This is proof of concept, that DSA arch runs can be used in place of CTA/CTP in patients likely to require intra-arterial therapy.Disclosure: Dr. Campbell has nothing to disclose. Dr. Jadhav has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Campbell, D., Jadhav, A. Tags: Cerebrovascular Disease and Interventional Neurology I ePosters Source Type: research
Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial
This study is registered with ClinicalTrials.gov, number NCT00427388. Findings Patients were recruited between June 21, 2007, and Dec 19, 2013. Complete 30-day data was available for all 7507 patients randomly assigned to methylprednisolone (n=3755) and to placebo (n=3752). Methylprednisolone, compared with placebo, did not reduce the risk of death at 30 days (154 [4%] vs 177 [5%] patients; relative risk [RR] 0·87, 95% CI 0·70–1·07, p=0·19) or the risk of death or major morbidity (909 [24%] vs 885 [24%]; RR 1·03, 95% CI 0·95–1·11, p=0·52). The most common safety outcomes in the methylprednisolone and placebo g...
Source: The Lancet - September 26, 2015 Category: Journals (General) Source Type: research
Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.PMID:33898022 | PMC:PMC8053362 | DOI:10.1016/j.amsu.2021.102309
Source: Annals of Medicine - April 26, 2021 Category: Internal Medicine Authors: Abdelilah El Rhalete Inas Rhazi Amine Bensaid Ikram Zaid Houssam Bkiyer Nabila Ismaili Nouha Elouafi Brahim Housni Source Type: research
Clinicohistological Profile and Outcomes of Rapidly Progressive Glomerulonephritis: A Prospective Study from North India
This study included 40 patients of biopsy-proven RPGN. The diagnosis of RPGN was based on renal histology showing crescents in >50% of glomeruli. All patients were given induction with intravenous (IV) methylprednisolone (0.5 g) for three days followed by maintenance with oral prednisolone (1 mg/kg/day) and six IV pulses of cyclophosphamide (0.5 g) given fortnightly followed by maintenance therapy with azathioprine (2 mg/kg/day). The outcomes were recorded. Three-fourth of the patients (77.4%) required renal replacement therapy (RRT) at diagnosis. More than half of patients (57.5%) were antineutrophil cytoplasmic antibo...
Source: Saudi Journal of Kidney Diseases and Transplantation - January 17, 2023 Category: Urology & Nephrology Authors: Deepak Sharma Sudhir Mehta Jasvinder Singh Sandhu Preet Mohinder Sohal Vikas Makkar Source Type: research
